Author Archives: Admin

Scientific and Commercial Breakthroughs Developed by Kraig Biocraft Laboratories Featured in Technology Review

LANSING, MI–November 4, 2010- Kraig Biocraft Laboratories Inc. (KBLB) announces that Technology Review, published by the Massachusetts Institute of Technology, recently featured the company in its article titled, “Transgenic Worms Make Tough Fibers,” which is available online at http://www.technologyreview.com/biomedicine/26623/.

“MIT’s Technology Review is a very prestigious publication, and we are pleased with the interest in our company,” said Kim Thompson, Kraig Biocraft Laboratories CEO and founder. “The fact that Technology Review featured Kraig’s recent genetic engineering breakthroughs as the headlining story highlights the importance and commercial potential of this new technology. Frankly, our research team has earned these accolades by creating a technology that has the potential to revolutionize material science and have an exciting and positive impact on the textile markets.”

To learn more about company’s recent commercial and scientific breakthrough, visit KraigLabs.com.

The Kraig Labs Web site (www.KraigLabs.com) currently hosts several short videos that describe the technological breakthrough and outlines the commercial potential, which garnered attention in the scientific and trade journals. Also available on the Web site is the company’s recent CEO shareholder conference call.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research and create commercially-viable products may be affected by the competitive environment, the company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

This entry was posted on by .

Kraig Biocraft Laboratories’ Data Feed was Temporarily Disrupted on Thursday October 7, 2010

Kraig Biocraft Laboratories, Inc. (KBLB) announced today that numerous financial websites experienced a temporary disruption in their Company related data stream on October 7, 2010.

The data stream interruption was the result of the largest market makers changing trading platforms. “Apparently the largest market makers have decided to run their trades through the pink sheet system because of dramatic increases in OTCBB trading fees,” said CEO Kim Thompson. “The change had nothing to do with our corporate activity. We remain current on all of our filings and will of course remain a reporting company. Our third quarter just ended a few days ago on September 30th, and we anticipate filing our 10Q in record time for Kraig.”

The migration of market makers from the OTCBB to the Pink Sheet trading platform apparently began accelerating when the OTCBB decided to increase the fees it charges market makers. When market makers run their trades through a rival platform and give no part of their business in a security to the OTCBB for a period of four days or more, the OTCBB can list the subject security on its daily list under rule 15c2-11. For reasons which have not been explained by the OTCBB, this action resulted in the data stream disruption as the OTCBB did not bother to provide advance notice to the financial service websites, to the company or, apparently, even to its market makers.

During the disruption the Company publicized that current data might be obtained by adding .pk to the Company’s symbol. As of this writing, it appears that that is not necessary and that data flow has been restored to KBLB. The Company thanks all of the financial service websites and information technologies professionals who worked during the day to restore the flow of information.

As a reminder, the Company will be hosting a conference call today, Friday October 8, 2010 at 4:30 PM EDT. Please check our public announcement of earlier today for conference details.

 

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com .

 

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495, benhansel@yahoo.com

This entry was posted on by .

Kraig Biocraft Laboratories Shareholder Conference Call Today, Friday, October 8, 2010

LANSING, MI — (Marketwire) — 10/08/10 — Kraig Biocraft Laboratories, Inc. (KBLB) reminds all current, new and prospective shareholders that the Company’s CEO will conduct a shareholder conference call today, Friday, October 8, 2010 at 4:30 p.m. EDT.

Kim Thompson, the Company’s CEO and founder, will review the recent development of recombinant spider silk technology, the Company’s intellectual property and commercialization rights to this technology, as well as what is in the research and development pipeline.

Interested parties should dial the toll-free numbers below in the order provided. If the first number does not connect, please dial the next number below.

1. 866-906-9888 and when prompted enter access code 3535794 followed by the # (pound) sign.

2. 866-506-1209 and when prompted enter access code 3535794 followed by the # (pound) sign.

3. 866-939-8416 and when prompted enter access code 3535794 followed by the # (pound) sign.

It is recommended that callers dial in approximately five minutes before the conference is scheduled to begin.

Shareholders are invited to submit questions to benh@ttfsco.com prior to noon today. For interested parties who are unable to make today’s call, the Company anticipates posting a recording of the conference call on the Company website sometime in the near future.

All interested parties are encouraged by the Company to use the following link to view a video of the public announcement concerning the recent scientific breakthrough in order to be prepared for the conference call. http://www.youtube.com/watch?v=GnUupDb2Mvo

Additional information is available on Kraig Biocraft Laboratories web site: https://kraiglabs.com.

Conference call: 4:30 p.m. EDT (Eastern Daylight Time) today, Friday, October 8, 2010.

 

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact: Ben Hansel (720) 288-8495, benhansel@yahoo.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Application for Trademark of Spider Silk Brands

LANSING, MI–October 5, 2010- Kraig Biocraft Laboratories, Inc. (KBLB) announced today that that it has filed intent to use applications with the US Patent and Trademark office seeking registration of numerous marks for the purpose of branding recombinant silk fibers.

“The Company views branding of our recombinant silk to be just as important as it is with any other product line. It is anticipated that the proposed marks will enhance product marketability and distinguish our advanced technology from other fibers in the marketplace,” said Kim Thompson, the Company’s CEO and founder. “This is just the beginning of the Company’s efforts to further distinguish itself in the market place as we move toward the commercialization of our technology.”

The intent to use applications included seven separate proposed marks including Spiderpillar™ and Monster Silk™.

The Company recently announced the successful development of recombinant spider silk based fibers using genetic engineering. A video of that press conference can be viewed on the Company web site or at http://www.youtube.com/watch?v=GnUupDb2Mvo

The Company will also hold a shareholder press conference on Friday, October 8, 2010 at 4:30 p.m. EDT and will issue a reminder press release the morning of the conference call, which will include the phone number and access code instructions.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

This entry was posted on by .

Kraig Biocraft Laboratories to Hold Shareholder Conference Call to Discuss Spider Silk Commercialization and Intellectual Property

LANSING, MI–October 1, 2010-  Kraig Biocraft Laboratories, Inc. (KBLB) announces today that Kim Thompson cordially invites all current, new and prospective shareholders to participate in the Company’s conference call to be held on Friday, October 8, 2010 at 4:30 p.m. EDT.

Thompson, the Company’s CEO and Founder, will review the recent development of recombinant spider silk, the Company’s intellectual property and commercialization rights to this powerful technology, as well as what is in the pipeline for near term research and development payoff, followed by a question and answer period.

The conference call phone number and other details will be announced in a follow-up company release early next week. Shareholders are invited to submit questions to benh@ttfsco.com prior to the event.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com.

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:
Ben Hansel
(720) 288-8495
benh@ttfsco.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Patent Filing on Artificial Spider Silk Breakthrough

Kraig Exercises Option for Exclusive Commercial License

SOUTH BEND, IN — (Marketwire) — 09/30/10 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that a provisional patent application has been filed by the University of Notre Dame on the artificial spider silk technology revealed at the Company’s joint press conference yesterday with the University of Notre Dame. The patent filing covers all of the breakthrough technology revealed at the press conference, including artificial spider silk and the methods used to create transgenic silkworms capable of spinning artificial spider silk and recombinant fiber.

Pursuant to the provisions of Kraig Biocraft Laboratories collaborative research and intellectual property agreement with the University, the Company has an option for a global exclusive license to use the technology commercially. The Company is happy to inform its shareholders that it has now exercised that option.

“We built this company with this moment in mind. Our exclusive commercial license was essentially pre-negotiated at the time we entered into the collaborative research agreement,” explained CEO Kim Thompson. “The next few months will be a very exciting time for Kraig as we work toward our vision for commercialization of this new and exciting technology. We are rapidly moving from being exclusively research and development to entering a marketable product and deliverable biotechnology stage.”

For more information on the University’s view of this spider silk technology breakthrough you can visit http://newsinfo.nd.edu/ .

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

 

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Ben Hansel (720) 288-8495

This entry was posted on by .

University of Notre Dame and Kraig Biocraft Laboratories Create Artificial Spider Silk Breakthrough

SOUTH BEND, IN, Sep 29, 2010 — Kraig Biocraft Laboratories, (OTCBB: KBLB ) is very pleased to announce that the following release was made by the University of Notre Dame moments ago.

Notre Dame and University of Wyoming scientists genetically engineer silkworms to produce artificial spider silk

A research and development effort by the University of Notre Dame, the University of Wyoming, and Kraig Biocraft Laboratories, Inc. has succeeded in producing transgenic silkworms capable of spinning artificial spider silks.

“This research represents a significant breakthrough in the development of superior silk fibers for both medical and non-medical applications,” said Malcolm J. Fraser Jr., a Notre Dame professor of biological sciences. “The generation of silk fibers having the properties of spider silks has been one of the important goals in materials science.”

Natural spider silks have a number of unusual physical properties, including significantly higher tensile strength and elasticity than naturally spun silkworm fibers. The artificial spider silks produced in these transgenic silkworms have similar properties of strength and flexibility to native spider silk.

Silk fibers have many current and possible future biomedical applications, such as use as fine suture materials, improved wound healing bandages, or natural scaffolds for tendon and ligament repair or replacement. Spider silk-like fibers may also have applications beyond biomedical uses, such as in bulletproof vests, strong and lightweight structural fabrics, a new generation athletic clothing and improved automobile airbags.

Until this breakthrough, only very small quantities of artificial spider silk had ever been produced in laboratories, but there was no commercially viable way to produce and spin these artificial silk proteins. Kraig Biocraft believed these limitations could be overcome by using recombinant DNA to develop a bio-technological approach for the production of silk fibers with a much broader range of physical properties or with pre-determined properties, optimized for specific biomedical or other applications.

The firm entered into a research agreement with Fraser, who discovered and patented a powerful and unique genetic engineering tool called “piggyBac.” PiggyBac is a piece of DNA — known as a transposon that can insert itself into the genetic machinery of a cell.

“Several years ago, we discovered that the piggyBac transposon could be useful for genetic engineering of the silkworm, and the possibilities for using this commercial protein production platform began to become apparent.”

Fraser, with the assistance of University of Wyoming researcher Randy Lewis, a biochemist who is one of the world’s foremost authorities on spider silk, and Don Jarvis, a noted molecular geneticist who specializes in insect protein production, genetically engineered silkworms in which they incorporated specific DNAs taken from spiders. When these transgenic silkworms spin their cocoons, the silk produced is not ordinary silkworm silk, but, rather, a combination of silkworm silk and spider silk. The genetically engineered silk protein produced by the transgenic silkworms has markedly improved elasticity and strength approaching that of native spider silk.

“We’ve also made strides in improving the process of genetic engineering of these animals so that the development of additional transgenics is facilitated,” Fraser said. “This will allow us to more rapidly assess the effectiveness of our gene manipulations in continued development of specialized silk fibers.”

Since silkworms are already a commercially viable silk production platform, these genetically engineered silkworms effectively solve the problem of large scale production of engineered protein fibers in an economically practical way.

“Using this entirely unique approach, we have confirmed that transgenic silkworms can be a potentially viable commercial platform for production of genetically engineered silk proteins having customizable properties of strength and elasticity,” Fraser said. “We may even be able to genetically engineer fibers that exceed the remarkable properties of native spider silk.”

The genetic engineering breakthrough was announced today (Sept. 29) by Dr. Fraser, Dr. Lewis and Kraig Biocraft CEO Kim Thompson at a press conference on the Notre Dame campus.

 

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

 

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT:

Ben Hansel (720) 288-8495

Email Contact:

benhansel@yahoo.com

This entry was posted on by .

University of Notre Dame and Kraig Biocraft Laboratories to Hold Joint Press Conference

LANSING, Mich., September 24, 2010 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that the University of Notre Dame and Kraig Biocraft Laboratories will hold a joint press conference Wednesday, September 29, 2010 on the Notre Dame campus to describe a new research breakthrough and its possible biomedical and commercial applications.

The press conference will take place in the University of Notre Dame’s Jordan Hall of Science at 11:00 A.M. Due to space limitations, media only please. For invitations and further details the media are invited to contact Ben Hansel (720) 288-8495.

 

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

 

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Ben Hansel (720) 288-8495 benhansel@yahoo.com

This entry was posted on by .

Kraig Biocraft Laboratories Press Conference Update

LANSING, Mich., September 20, 2010 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced that the company anticipates releasing definitive details about its upcoming press conference, including date, time and place, later this week.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: https://kraiglabs.com

 

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: CONTACT: Ben Hansel (720) 288-8495

This entry was posted on by .

Kraig Biocraft Laboratories, Inc. Successfully Creates Mutant Spider-Moths With Gene Splicing Technology

LANSING, MI — (Marketwire) — 09/13/10 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of spider silk based materials, today updated its press release from September 7 by confirming that scientists working in collaboration with the Company have successfully genetically engineered silkworm moths with select spider genes.

The spider-moths were developed as a part of the Company’s product development program that is aimed at utilizing transgenic silkworms to produce spider silk. The Company believes that spider silk has numerous potential commercial and industrial applications in the hundred billion dollar technical textiles market.

The silkworms were successfully genetically engineered with the Company’s targeted spider silk DNA sequences.

“In response to the feedback from our September 7th press release regarding genetically engineered silkworm, we are happy to readdress our press release here in layman’s terms. While transgenic silkworm is the proper scientific term, laymen may better understand what we have accomplished as genetically engineered spider-moths,” said CEO Kim K. Thompson. “The genetically engineered silkworms are true moths which have been transformed with only one carefully targeted spider silk gene sequence. That gene sequence relates specifically to silk production.”

Thompson added, “We believe that the spider DNA has fully integrated into the silkworm chromosome. This genetic engineering success clears a major hurdle in our path; it puts us well ahead of our product development schedule and will allow us to further accelerate product development.”

The Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month.

 

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

 

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:
Kraig Biocraft Laboratories, Inc.
Kim K. Thompson
CEO
(517) 336-0807

This entry was posted on by .